Indeed in this fascinating interview, CEO Adam Hill explains how this leading immunodiagnostics firm with 1st class expertise in autoantibodies – is becoming increasingly embedded in the drug discovery & pre-clinical testing fabric of many of the world’s largest BioPharma groups.
00:00 What’s been driving the demand & series of new orders within ImmunoINSIGHTS?
02:25 Importance & scope of Master Services Agreements
08:30 Applicability of ONC’s technology to latest new therapies
11:30 Possible future investments
13:05 Expectations fro FY’23 & beyond
16:05 Progress at EarlyCDT Lung & strategic options
19:50 Future newsflow
#Oncimmune #ONC
